Structure–Activity Relationship Studies of Hemicholinium (HC-3) Congeners

Joseph G. Cannon, Teresa M.L. Lee, Y. a. Chang, Alfred M. Nyanda, Bula Bhattacharyya, Jan R. Flynn, Tapan Chatterjee, Ranbir K. Bhatnagar, John Paul Long

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

In a continuing investigation of structural requirements for hemicholinium-like activity (inhibition of neuromuscular transmission due to inhibition of uptake of choline into nerve terminals), some additional molecular modifications of hemicholinium (“HC-3”; structure 1) were made. The target compounds were prepared by standard one- or two-step sequences. Noncyclic acetal moieties in general permitted retention of pharmacological activity, as did concomitant replacement of the central bi-phenyl “spacer” by other bulky cyclic groupings and replacement of the oxazinium rings by piperidine or 4-methylpiperidine. However, these modifications generally produced compounds of a lower potency. Replacement of the biphenyl moiety of HC-3 with polyalkylene chains permitted retention of a considerable degree of activity. In these target compounds, the two quaternary nitrogens can exist the same distance apart (approximately 14 Å) as in the hemicholinium molecule. The ditertiary amino congener of a pharmacologically active bis-quaternary oxazinium compound was almost completely inactive. To date, only one tertiary amine has been found which displays a significant degree of hemicholinium-like activity.

Original languageEnglish (US)
Pages (from-to)359-364
Number of pages6
JournalPharmaceutical Research: An Official Journal of the American Association of Pharmaceutical Scientists
Volume5
Issue number6
DOIs
StatePublished - Jan 1 1988

Fingerprint

Hemicholinium 3
Acetals
Choline
Amines
Nitrogen
Pharmacology
Molecules

Keywords

  • hemicholinium
  • inhibition of choline uptake
  • neuromuscular inhibition

ASJC Scopus subject areas

  • Biotechnology
  • Molecular Medicine
  • Pharmacology
  • Pharmaceutical Science
  • Organic Chemistry
  • Pharmacology (medical)

Cite this

Structure–Activity Relationship Studies of Hemicholinium (HC-3) Congeners. / Cannon, Joseph G.; Lee, Teresa M.L.; Chang, Y. a.; Nyanda, Alfred M.; Bhattacharyya, Bula; Flynn, Jan R.; Chatterjee, Tapan; Bhatnagar, Ranbir K.; Long, John Paul.

In: Pharmaceutical Research: An Official Journal of the American Association of Pharmaceutical Scientists, Vol. 5, No. 6, 01.01.1988, p. 359-364.

Research output: Contribution to journalArticle

Cannon, JG, Lee, TML, Chang, YA, Nyanda, AM, Bhattacharyya, B, Flynn, JR, Chatterjee, T, Bhatnagar, RK & Long, JP 1988, 'Structure–Activity Relationship Studies of Hemicholinium (HC-3) Congeners', Pharmaceutical Research: An Official Journal of the American Association of Pharmaceutical Scientists, vol. 5, no. 6, pp. 359-364. https://doi.org/10.1023/A:1015955527100
Cannon, Joseph G. ; Lee, Teresa M.L. ; Chang, Y. a. ; Nyanda, Alfred M. ; Bhattacharyya, Bula ; Flynn, Jan R. ; Chatterjee, Tapan ; Bhatnagar, Ranbir K. ; Long, John Paul. / Structure–Activity Relationship Studies of Hemicholinium (HC-3) Congeners. In: Pharmaceutical Research: An Official Journal of the American Association of Pharmaceutical Scientists. 1988 ; Vol. 5, No. 6. pp. 359-364.
@article{d6419802770d4339a3701aaedcb43095,
title = "Structure–Activity Relationship Studies of Hemicholinium (HC-3) Congeners",
abstract = "In a continuing investigation of structural requirements for hemicholinium-like activity (inhibition of neuromuscular transmission due to inhibition of uptake of choline into nerve terminals), some additional molecular modifications of hemicholinium (“HC-3”; structure 1) were made. The target compounds were prepared by standard one- or two-step sequences. Noncyclic acetal moieties in general permitted retention of pharmacological activity, as did concomitant replacement of the central bi-phenyl “spacer” by other bulky cyclic groupings and replacement of the oxazinium rings by piperidine or 4-methylpiperidine. However, these modifications generally produced compounds of a lower potency. Replacement of the biphenyl moiety of HC-3 with polyalkylene chains permitted retention of a considerable degree of activity. In these target compounds, the two quaternary nitrogens can exist the same distance apart (approximately 14 {\AA}) as in the hemicholinium molecule. The ditertiary amino congener of a pharmacologically active bis-quaternary oxazinium compound was almost completely inactive. To date, only one tertiary amine has been found which displays a significant degree of hemicholinium-like activity.",
keywords = "hemicholinium, inhibition of choline uptake, neuromuscular inhibition",
author = "Cannon, {Joseph G.} and Lee, {Teresa M.L.} and Chang, {Y. a.} and Nyanda, {Alfred M.} and Bula Bhattacharyya and Flynn, {Jan R.} and Tapan Chatterjee and Bhatnagar, {Ranbir K.} and Long, {John Paul}",
year = "1988",
month = "1",
day = "1",
doi = "10.1023/A:1015955527100",
language = "English (US)",
volume = "5",
pages = "359--364",
journal = "Pharmaceutical Research",
issn = "0724-8741",
publisher = "Springer New York",
number = "6",

}

TY - JOUR

T1 - Structure–Activity Relationship Studies of Hemicholinium (HC-3) Congeners

AU - Cannon, Joseph G.

AU - Lee, Teresa M.L.

AU - Chang, Y. a.

AU - Nyanda, Alfred M.

AU - Bhattacharyya, Bula

AU - Flynn, Jan R.

AU - Chatterjee, Tapan

AU - Bhatnagar, Ranbir K.

AU - Long, John Paul

PY - 1988/1/1

Y1 - 1988/1/1

N2 - In a continuing investigation of structural requirements for hemicholinium-like activity (inhibition of neuromuscular transmission due to inhibition of uptake of choline into nerve terminals), some additional molecular modifications of hemicholinium (“HC-3”; structure 1) were made. The target compounds were prepared by standard one- or two-step sequences. Noncyclic acetal moieties in general permitted retention of pharmacological activity, as did concomitant replacement of the central bi-phenyl “spacer” by other bulky cyclic groupings and replacement of the oxazinium rings by piperidine or 4-methylpiperidine. However, these modifications generally produced compounds of a lower potency. Replacement of the biphenyl moiety of HC-3 with polyalkylene chains permitted retention of a considerable degree of activity. In these target compounds, the two quaternary nitrogens can exist the same distance apart (approximately 14 Å) as in the hemicholinium molecule. The ditertiary amino congener of a pharmacologically active bis-quaternary oxazinium compound was almost completely inactive. To date, only one tertiary amine has been found which displays a significant degree of hemicholinium-like activity.

AB - In a continuing investigation of structural requirements for hemicholinium-like activity (inhibition of neuromuscular transmission due to inhibition of uptake of choline into nerve terminals), some additional molecular modifications of hemicholinium (“HC-3”; structure 1) were made. The target compounds were prepared by standard one- or two-step sequences. Noncyclic acetal moieties in general permitted retention of pharmacological activity, as did concomitant replacement of the central bi-phenyl “spacer” by other bulky cyclic groupings and replacement of the oxazinium rings by piperidine or 4-methylpiperidine. However, these modifications generally produced compounds of a lower potency. Replacement of the biphenyl moiety of HC-3 with polyalkylene chains permitted retention of a considerable degree of activity. In these target compounds, the two quaternary nitrogens can exist the same distance apart (approximately 14 Å) as in the hemicholinium molecule. The ditertiary amino congener of a pharmacologically active bis-quaternary oxazinium compound was almost completely inactive. To date, only one tertiary amine has been found which displays a significant degree of hemicholinium-like activity.

KW - hemicholinium

KW - inhibition of choline uptake

KW - neuromuscular inhibition

UR - http://www.scopus.com/inward/record.url?scp=0023815187&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0023815187&partnerID=8YFLogxK

U2 - 10.1023/A:1015955527100

DO - 10.1023/A:1015955527100

M3 - Article

C2 - 2854255

AN - SCOPUS:0023815187

VL - 5

SP - 359

EP - 364

JO - Pharmaceutical Research

JF - Pharmaceutical Research

SN - 0724-8741

IS - 6

ER -